Table 2.

Treatment response for patients available for analysis (n = 22).

Completed all 4 cycles
Yes	12
No	10
Progression in primary	5
Progression (metastatic)	1
Toxicity	4
Definitive surgery
Yes
Breast conservation	5
Mastectomy	16
No
Metastatic disease progression	1
Residual cancer burden
0–I	5
II–III	16